Physician responses to question about penetrance of HNPCC associated mutations, by specialty, practice characteristics, and age
| Characteristics | In your opinion, what percentage of patients who carry a gene for hereditary non-polyposis colorectal cancer will actually go on to develop colorectal cancer?* | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <50 (%) | ⩾50 (%) | Not sure (%) | OR† | 95% CI | ||||||
| *Unadjusted percentages representing physician responses are weighted to the U.S. population of physicians in the selected specialties. Row percentages may not add to 100% due to item nonresponse. The dependent variable in the logistic regression model is understanding that ⩾50% of carriers of HNPCC associated germline mutations develop colorectal cancer (versus <50% or not sure as the referent category). Weighted ORs and 95% CI are adjusted for all variables in the table. HMO, health maintenance organisation. | ||||||||||
| Total | 33.6 | 13.1 | 50.9 | |||||||
| Medical specialty | ||||||||||
| Family/general practice | 30.0 | 9.3 | 58.1 | 1.0 | – | |||||
| Internal medicine | 32.4 | 17.5 | 46.7 | 1.9 | 1.1–3.0 | |||||
| Obstetricians/gynaecologists | 35.9 | 5.2 | 57.6 | 0.5 | 0.2–1.1 | |||||
| Oncologists | 44.1 | 25.1 | 27.1 | 2.7 | 1.5–4.8 | |||||
| General surgeons | 38.0 | 11.2 | 50.1 | 1.2 | 0.6–2.4 | |||||
| Gastroenterologists | 49.4 | 38.9 | 11.7 | 6.1 | 2.8–13.4 | |||||
| Age | ||||||||||
| ⩾60 | 34.2 | 5.9 | 57.6 | 1.0 | – | |||||
| 40–59 | 33.8 | 13.1 | 50.5 | 1.9 | 1.0–3.8 | |||||
| <40 | 32.2 | 19.0 | 46.6 | 2.7 | 1.3–5.9 | |||||
| Cancer genetics services provided in past 12 months | ||||||||||
| None | 30.9 | 12.4 | 54.3 | 1.0 | – | |||||
| Did not order colon cancer genetics tests, but did order other cancer genetics tests or referred patients elsewhere for testing or risk assessment | 37.9 | 15.0 | 45.5 | 1.3 | 0.8–2.1 | |||||
| Ordered colon cancer tests but did not refer patients elsewhere | 40.8 | 18.5 | 35.2 | 0.9 | 0.3–2.8 | |||||
| Both ordered a colon test and referred patients elsewhere | 67.8 | 13.7 | 18.5 | 0.9 | 0.3–3.2 | |||||
| Local facilities for genetic counselling and testing for inherited cancer risk | ||||||||||
| No | 42.1 | 13.8 | 42.7 | 1.0 | – | |||||
| Yes | 37.1 | 14.5 | 46.6 | 1.0 | 0.5–1.8 | |||||
| Not sure | 26.3 | 11.1 | 60.0 | 0.8 | 0.4–1.6 | |||||
| Clear guidelines or strategies are not available for managing patients with inherited cancer susceptibility mutations | ||||||||||
| Agreed with statement, somewhat or strongly | 38.6 | 13.8 | 47.0 | 1.0 | – | |||||
| Disagreed, somewhat or strongly | 30.9 | 19.2 | 49.9 | 1.2 | 0.7–2.1 | |||||
| Not sure | 13.9 | 7.2 | 78.1 | 0.6 | 0.3–1.2 | |||||
| Received cancer genetic test advertising | ||||||||||
| No or not sure | 30.9 | 12.8 | 54.0 | 1.0 | – | |||||
| Yes | 40.7 | 14.1 | 43.6 | 1.1 | 0.7–1.7 | |||||
| Academic affiliation | ||||||||||
| No | 31.9 | 11.4 | 54.3 | 1.0 | – | |||||
| Yes | 36.3 | 16.3 | 45.6 | 1.3 | 0.9–2.0 | |||||
| Practice arrangement | ||||||||||
| Full or part owner | 33.8 | 10.3 | 53.0 | 1.0 | – | |||||
| Employee of physician practice, HMO, hospital, university, or clinic | 33.1 | 16.9 | 48.7 | 1.6 | 1.0–2.4 | |||||
| Specialties in the practice | ||||||||||
| Single specialty | 33.9 | 11.8 | 51.9 | 1.0 | – | |||||
| Multi specialty | 32.9 | 17.6 | 48.6 | 1.1 | 0.7–1.6 | |||||